



December 19, 2022

Paul Hays
Noble Pharma, LLC
4602 Domain Drive
Menomonie, WI 54751

Sent via email to: paulh@noblepharmallc.com

Dear Petitioner:

Your submission requesting that the Commissioner file an Abbreviated New Animal Drug (ANADA) for a different dosage form of an approved pioneer product was received and processed under CFR 10.30 by this office on 12/19/2022.

It was assigned docket number FDA-2022-P-3260. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note, the acceptance of the suitability petition for filing is a procedural matter and in no way reflects the Agency's decision on the substantive merits of the petition.

Sincerely,

Karen Malvin
Acting Director
Dockets Management Staff
FDA/Office of Operations (OO)